

Docket No.: 10806-106

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage to first class mail in an envelope addressed to: Box Fee Amendment; Assistant Commissioner for Patents, Washington, DC 20231 on December 8, 2000.



RECEIVED
DEC 18 2000
16148
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stjernschantz et al : Paper No. _____
Serial No.: 09/445,919 : Group Art Unit: 1614
Filed: March 16, 2000 : Examiner: Z. Fay
For: **Prostaglandin Derivatives Devoid of Side-Effects for the Treatment of Glaucoma**

Box Fee Amendment
Assistant Commissioner for Patents
Washington, D. C. 20231

Dear Sir:

Transmitted herewith is an Amendment in the above-identified application.

☐ No additional fee is required.

☐ Also attached:

The fee has been calculated as shown below:

	NO. OF CLAIMS	HIGHEST PREVIOUS PAID FOR	EXTRA CLAIMS	RATE	FEE
Total Claims	22	20	2	x \$18 =	\$36.00
Independent Claims	3	3	0	x \$80 =	\$
If multiple claims newly presented, add \$270.00					-----
TOTAL FEE DUE					\$36.00

☐ A check in the amount of \$ is enclosed.

☐ Please charge my Deposit Account No. 04-1133 in the amount of \$36.00.

☒ The Commissioner is hereby authorized to charge payment of any additional fees associated with this communication or credit any overpayment, to Deposit Account No. 04-1133, including any filing fees under 37 CFR 1.16 for presentation of extra claims and any patent application processing fees under 37 CFR 1.17.

Respectfully submitted,

Holly D. Kozlowski
Registration No. 30,468


DINSMORE & SHOHL LLP
1900 Chemed Center
255 East Fifth Street
Cincinnati, Ohio 45202
(513) 977-8568
Date: December 8, 2000
628658.01

Docket No. 10806-106

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231 on December 8, 2000.

[Signature]



PATENT

RECEIVED

DEC 18 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Johan Stjernschantz et al : Paper No.: ____
Serial No.: 09/445,919 : Group Art Unit: 1614
Filed: March 16, 2000 : Examiner: Z. Fay

[Handwritten initials]

For: **Prostaglandin Derivatives Devoid of Side-Effects for the Treatment of Glaucoma**

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Official Action dated September 8, 2000, please amend the present application as follows:

In the Specification:

Page 1, line 6, after "compounds", insert --that are--.

Page 14, line 11, change "15RS-16,16-trimethylene-PGE₂" to --15RS-16,16-trimethylene-PGE₂--

Page 14, line 14, change "2,2-trimethylhexanote" to --2,2-trimethylenehexanote--.

In the Claims:

[Handwritten mark] Please add the following claims 22-23:

[Handwritten mark] --22. (New) A method of treating glaucoma or ocular hypertension in a subject's eye while reducing melanogenesis, which method comprises contacting the surface of the eye with an

12/14/2000 MMARMDL 00000002 041133 09445919

01 FC:103

36.00 CH

[Handwritten mark]